Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
Seminars in Oncology|November 29, 2015
Overcoming Resistance to Targeted Therapies in CancerKeara L Redmond, Anastasia Papafili, Mark Lawler, et al.
Nature Reviews. Cancer|September 25, 2013
Cancer drug resistance: an evolving paradigmCaitriona Holohan, Sandra Van Schaeybroeck, Daniel B Longley, et al.
Nature Reviews. Clinical Oncology|February 16, 2011
Implementing prognostic and predictive biomarkers in CRC clinical trialsSandra Van Schaeybroeck, Wendy L Allen, Richard C Turkington, et al.
The Biochemical Journal|December 13, 2016
Deubiquitylating enzymes in receptor endocytosis and traffickingAidan P McCann, Christopher J Scott, Sandra Van Schaeybroeck, et al.
Bioorganic & Medicinal Chemistry Letters|August 31, 2015
Probing a 3,4'-bis-guanidinium diaryl derivative as an allosteric inhibitor of the Ras pathwayElena Diez-Cecilia, Robert Carson, Brendan Kelly, et al.
Frontiers in Pharmacology|August 30, 2021
A Nudibranch Marine Extract Selectively Chemosensitizes Colorectal Cancer Cells by Inducing ROS-Mediated Endoplasmic Reticulum StressVerónica Ruiz-Torres, Nicholas Forsythe, Almudena Pérez-Sánchez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2010
Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancerJoan N Kyula, Sandra Van Schaeybroeck, Joanne Doherty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2005
Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapySandra Van Schaeybroeck, Anthi Karaiskou-McCaul, Donal Kelly, et al.
Cancer Research|October 17, 2008
Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAILSandra Van Schaeybroeck, Donal M Kelly, Joan Kyula, et al.
BMC Systems Biology|September 11, 2015
Connectivity mapping using a combined gene signature from multiple colorectal cancer datasets identified candidate drugs including existing chemotherapiesQing Wen, Paul O'Reilly, Philip D Dunne, et al.
Pageof 5